REG - Medpal AI PLC - Launch of New Health dedicated GLP/peptides brand

Medpal AIAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260520:nRST9891Ea&default-theme=true

RNS Number : 9891E  Medpal AI PLC  20 May 2026

20 May 2026

MedPal AI plc

("MedPal AI" or the "Company")

Launch of New Health on new.co.uk as dedicated GLP-1 and peptides brand

New Health to operate as a specialist consumer brand within MedPal AI,
positioned for GLP-1 growth and the expected UK oral GLP-1 step-change

 

MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy
platform, is pleased to announce the launch of New Health, a dedicated
consumer sub-brand focused on the GLP-1 weight-management and broader peptide
medicines market opportunity, supported by a £1.3 million national consumer
marketing campaign. The launch is being positioned in the context of rapid
growth in the GLP-1 category and ahead of the Board's anticipated UK approval
of Novo Nordisk's once-daily weight-management pill in summer 2026.

New Health will sit separately from the broader MedPal Clinic app and MedPal
consumer platform. It has been created to give the Company a sharper consumer
brand, acquisition funnel and patient journey for the highly competitive GLP-1
category, while continuing to use MedPal AI's regulated healthcare
infrastructure comprising: AI-assisted intake, clinician-led assessment,
prescribing where clinically appropriate, automated pharmacy dispensing and
ongoing monitoring.

Highlights

·      New Health launched as a specialist sub-brand of MedPal AI
focused initially on GLP-1 weight management and, over time, the broader
peptides opportunity.

·      The sub-brand will operate separately from the MedPal Clinic app
to allow a dedicated consumer proposition in a competitive, brand-led market,
while remaining fully connected to MedPal AI's clinical, pharmacy and
technology infrastructure.

·      £1.3 million has been committed to a national consumer marketing
programme, with performance-led digital activity expected to be a principal
component.

·      Marketing campaign is designed to drive traffic to websites
new.co.uk and new.uk, to increase initiations of qualified consultations and
to grow the New Health recurring patient base.

·      Market context supported by published research indicating
significant UK and global GLP-1 growth, including forecast UK prescription
weight-loss medication market growth at a CAGR of approximately 25% from 2026
to 2033.

·      The Board anticipates that the potential UK approval of Novo
Nordisk's oral Wegovy pill this summer could broaden the addressable market by
attracting patients who may not previously have considered injection-based
treatment.

·      New Health will be underpinned by MedPal AI's NHS-contracted
dispensing hubs in Runcorn and Swaffham, Distance Selling Pharmacy licences,
direct supply agreements with Eli Lilly and Novo Nordisk for current GLP-1
medicines, and an AI layer built on Google Vertex AI.

Strategic rationale: a focused sub-brand for a competitive market

The Board believes that the private GLP-1 weight-management market has become
one of the most competitive areas of consumer healthcare, with patients
comparing providers on the basis of brand trust, ease of access, clinical
governance, price, prescription fulfilment and ongoing support. In this
environment, the Board believes a specialist consumer brand is required to
compete effectively with established online weight-management providers and
pharmacy-led entrants.

New Health has, therefore, been created as a focused GLP-1 and peptides
sub-brand within MedPal AI, with its own consumer positioning, website,
campaign messaging and acquisition funnel. The purpose is not to replace the
MedPal Clinic app, but to sit alongside it. New Health provides a specialist
consumer entry point for this category, while the wider MedPal platform
remains the Company's health operating system and regulated care
infrastructure.

The Board believes this structure will allow MedPal AI to better compete at
the same level as dedicated consumer brands in the GLP-1 market, while
retaining the advantages of owned pharmacy infrastructure, human clinical
oversight, AI-assisted patient engagement and longitudinal monitoring.

Market context: GLP-1 growth and oral pill opportunity

The Board notes published market research indicating that the GLP-1 category
is expanding rapidly. Morgan Stanley Research has forecast that the global
market for GLP-1 treatments could reach approximately £140 billion by 2035,
more than double reported 2025 levels. In the UK, Grand View Research
estimates that the UK prescription weight-loss medications market was
approximately £313 million in 2025 and is projected to reach approximately
£1.85 billion by 2033, representing a compound annual growth rate of
approximately 25% from 2026 to 2033.

IQVIA evidence submitted to the UK Parliament also points to rapid
private-market growth, indicating that more than 2.37 million UK citizens had
access to GLP-1s in July 2025, of which approximately 200,000 accessed
treatment through the NHS. The Board believes this market backdrop supports
New Health operating as a distinct, focused MedPal AI sub-brand for GLP-1 and
peptide-led services.

The Board anticipates that Novo Nordisk's once-daily oral semaglutide 25 mg
weight-management pill, approved by the FDA in December 2025 and submitted to
the EMA and other regulatory authorities during the second half of 2025, could
receive UK approval during summer 2026. The Board believes that a pill-based
GLP-1 option could bring a new cohort of customers into the market, including
patients who may be reluctant to start injection-based treatment. There can be
no certainty as to UK regulatory approval, timing, supply, clinical
availability or prescribing requirements.

Marketing and patient acquisition

The £1.3 million marketing programme is intended to establish New Health as a
recognised consumer entry point for eligible patients seeking regulated
weight-management support. Target audiences will include UK adults actively
researching weight-loss support, GLP-1 treatment options, obesity and
metabolic health, as well as consumers who may become interested in
tablet-based or other peptide-led treatment options as and when they are
approved and clinically available in the UK. The Board expects oral GLP-1
availability, if approved, to broaden the top of the acquisition funnel and
bring a new cohort of customers into the category.

The marketing spend is expected to be phased over six months and
performance-led, with digital channels such as Google expected to be a
principal component. Management will monitor traffic to new.co.uk, initial
consultations, completed clinical assessments, conversion to new patient
sign-ups, retention, customer acquisition cost and gross contribution, with
the ability to increase, reduce or reallocate spend according to unit
economics, patient-safety requirements and clinical/pharmacy capacity.

All New Health services and communications will be delivered subject to
clinical eligibility, medicine availability, appropriate clinician review,
prescription-only medicine rules and all applicable UK pharmacy, clinical
governance and advertising requirements.

 

Related party Transaction

CEO Jason Drummond, owns the domain names new.co.uk and new.uk and has agreed
to licence them to the Company for nil consideration for an initial period of
six months. The provision of the domain licences constitutes a related party
transaction for the purposes of AIM Rule 13. The directors of the Company,
with the exception of Jason Drummond, having consulted with Cairn Financial
Advisers LLP, the Company's nominated adviser, consider that the terms of the
transaction are fair and reasonable insofar as the Company's shareholders are
concerned.

 

At the end of six months, the Company will have the option to acquire the
domain names.

 

Commenting on the launch, Jason Drummond, Founder and Chief Executive Officer
of MedPal AI plc, said:

"New Health is a focused sub-brand within MedPal AI for a specific
opportunity: GLP-1 weight management and the broader peptides category. This
market is highly competitive and brand-led, so we need a consumer proposition
that can compete on the same terms - a simple brand, a clear message, a
dedicated funnel and strong clinical governance behind it.

"MedPal AI remains the operating system for personal health. New Health is the
specialist point of access for patients seeking GLP-1 weight-management
support and, over time, broader peptide-led healthcare services where
clinically appropriate. The patient sees a clear consumer brand; behind it
sits MedPal's AI-assisted intake, clinicians, prescribing pathway, pharmacy
fulfilment and monitoring.

"Our £1.3 million marketing investment is designed to build New Health as a
scalable consumer channel, not as generic corporate advertising. The market
data supports the timing: published research points to rapid UK and global
growth in prescription weight-management medicines, and the Board anticipates
that the expected UK approval of Novo Nordisk's oral Wegovy pill this summer
could bring a new cohort of patients into the category. We will monitor
traffic, conversion, customer acquisition cost, retention and gross
contribution in real time and will scale spend only where the unit economics,
governance and capacity support it.

 

Watch an interview with Jason Drummond on the subject of the new brand at this
link:

https://www.youtube.com/watch?app=desktop&v=HjejrjlRG5Y&pp=iggCQAE%3D&ra=m
(https://www.youtube.com/watch?app=desktop&v=HjejrjlRG5Y&pp=iggCQAE%3D&ra=m)

 

Ends

 

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018). The Directors of the Company are
responsible for the contents of this announcement.

 

Enquiries

 MedPal AI plc                                           via Square1 Consulting

Jason Drummond, Founder & CEO
 Cairn Financial Advisers LLP (Nominated Adviser)        +44 (0) 20 7213 0880

Louise O'Driscoll / Jo Turner
 Oak Securities (a trading name of Merlin Partners LLP)  +44 (0) 20 3973 3678

Tim Dainton / Calvin Man
+44 (0) 7733 117328
 Clear Capital Markets Limited                           +44 (0) 20 3869 6080

Bob Roberts
 Square1 Consulting                                      +44 (0) 20 7929 5599

David Bick
+44 (0) 7831 381201

About MedPal AI plc

MedPal AI plc (AIM: MPAL; FRA: Z1N) is a UK-listed AI-native digital health
and pharmacy platform. The Company operates automated NHS-contracted
dispensing hubs in Runcorn and Swaffham and holds Distance Selling Pharmacy
licences. Its MedPal Clinic app and broader platform connect AI-assisted
patient engagement, clinical services and automated pharmacy fulfilment. New
Health is the Company's dedicated consumer sub-brand for GLP-1 weight
management and the broader peptide medicines opportunity. MedPal AI has direct
supply agreements with Eli Lilly and Novo Nordisk for current GLP-1 medicines.
The Company's AI layer runs on Google Vertex AI and supports patients through
WhatsApp and the MedPal consumer app.

Forward-looking statements

This announcement contains certain forward-looking statements, including
statements regarding the Company's strategy, expected market developments,
anticipated UK regulatory approval, timing and clinical availability of Novo
Nordisk's once-daily oral semaglutide 25 mg weight-management tablet, consumer
adoption, marketing activity, patient acquisition, customer acquisition cost,
return on marketing investment, the expected benefits of the New Health
sub-brand and future peptide medicines opportunities. Forward-looking
statements are based on current expectations and assumptions and are subject
to risks, uncertainties and other factors which may cause actual results,
performance or developments to differ materially. Market and industry data
cited in this announcement has been sourced from publicly available
third-party reports and has not been independently verified by the Company.
The Company does not undertake any obligation to update forward-looking
statements except as required by applicable law or regulation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLAKCBKKBKBAPD



            Copyright 2019 Regulatory News Service, all rights reserved